Introduction
Allogeneic stem cell transplantation (SCT) can cure malignant hematologic diseases such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS) and chronic myeloid leukemia (CML). 1 With the longer follow-up of these patients the importance of intermediate and long-term sequelae of SCT is increasing. 2 There is a close relationship between osteoblasts, osteoclasts and hematopoietic stem cells, 3 since osteoclasts develop from donor granulocyte-monocyte colony-forming units 4 and osteoblasts stem from mesenchymal stroma cells. 5 After allogeneic SCT the number of commited hematopoietic precursor cells in the bone marrow of the recipient is reduced for a prolonged period of time. 6 Long-lasting repopulation defects could therefore have an influence on the number and differentiation of bone precursor cells.
Intensive chemotherapy, immobilization in hospitalized patients, 7 graft-versus-host disease (GVHD) prophylaxis and GVHD therapy with cyclosporine A (CsA) 8 and steroids 9 and insufficient nutrition after transplant may have a negative impact on bone metabolism. Women carry an additional risk due to primary hypogonadism after high-dose chemo-and radiotherapy. 10 We have prospectively studied 67 patients after allogeneic transplantation for radiologic and biochemical changes in bone metabolism with the aim of defining risk groups for osteoporosis after SCT.
Materials and methods

Patients
Sixty-seven patients with ALL, AML, MDS and CML were prospectively studied after allogeneic SCT, which was performed between December 1996 and October 1999. Twenty-five of 47 patients (53%) with acute leukemias and 4/20 (20%) with CML had advanced diseases before SCT (Table 1) . Median interval between diagnosis and transplantation was 13 months (3-96), 6 months (3-45) for acute leukemias and 20 months (4-96) for CML patients.
CsA and methotrexate (MTX) were given as GVHD prophylaxis. 11 CsA was started on day −1 and was usually given for 6 months. Patients with a matched unrelated donor received prednisone 0.5 mg/kg from day 7 and 1.0 mg/kg from day 14 after SCT (Table 1) . First-line therapy of acute GVHD was performed with high-dose methylprednisolone. Chronic GVHD was treated with CsA, prednisone, mycophenolate mofetil, azathioprine and cyclophosphamide.
To prevent hypercatabolism all patients received total parenteral nutrition starting on the day of SCT (energy 30-32 kcal/kg, fluid 2.5-3.0 l, carbohydrates 4-5 g/kg, amino acids 1-1.5 g/kg, lipids 0.5 g/kg) supplemented with waterand lipid-soluble vitamins, minerals and trace elements. This included 220 IU vitamin D and 660 mg calcium per day. After a median of 19 days patients started to eat again.
Fourteen females received hormone replacement therapy after SCT.
All patients had given written informed consent for this study.
Study time points
Biochemical analyses were performed before start of conditioning therapy, weekly after SCT for 6 to 12 weeks and 6 and 12 months after SCT. Radiologic analysis was performed before start of conditioning therapy, 6 and 12 months after SCT.
Biochemical analysis of bone metabolism
Bone resorption was studied by measuring urinary excretion of pyridinium crosslinks and bone formation was studied by 
Bone mineral density
Lumbar bone mineral density (BMD) was measured by quantitative computed tomography (QCT) scan (Somatom Plus, Siemens, Mü nchen, Germany). After a lateral lumbar overview image, 3-mm slices were taken from the first to third lumbar vertebrae. Trabecular and cortical BMD were determined separately. Standardized BMD was calculated by comparing the individual BMD to European reference values. 12 Quality tests were performed by simultaneous calibration with a standardized phantom. The resulting BMD are expressed as Tscores (standard deviation of the individual BMD from the mean of young healthy persons averaging 30 years of age of same sex). Osteopenia was defined as a T-score within −1 and −2.5 s.d. of the mean value and osteoporosis as a T-score below −2.5 s.d. 13 
Statistics
Statistical analysis was performed with SPSS 9.0 by using twotailed t-tests. A difference of P Ͻ 0.05 was used as nominal level of significance if not otherwise stated. Analysis of two independent subgroups was performed using the Mann-Whitney U test; the Kruskal-Wallis H test was used for three or more independent subgroups. The Wilcoxon test was used between dependent subgroups.
Results
Sixty-four of 67 patients engrafted after SCT and reached complete remission; one patient was retransplanted after graft failure, one had refractory disease and one died early after SCT from acute GVHD. Hematopoietic reconstitution after SCT was normal (Table 1) . One year post-SCT 44 patients were alive, 23 were dead. Causes of death were primary disease in 12/23 patients and transplant-related causes in 11/23 patients.
Thirty-eight of 67 patients (57%) developed acute GVHD, 11/38 had grade III and IV. Twenty-seven of 60 evaluable patients (45%) developed chronic GVHD, 14/27 had extensive disease. Fourteen patients were excluded from pre-SCT analysis, because QCT was refused or not timely performed. Eight of the surviving patients after 6 months and 12 patients after 12 months were lost to follow-up or refused QCT at the given study time points.
Fifty-three patients were analyzed before SCT, 36 after 6 months and 32 after 12 months. Twenty-five patients underwent additional QCT measurements 18 and 24 months post-SCT.
Bone mineral density
BMD was reduced before SCT in 26/53 patients (49%) (Figure 1) .
Pathologic BMD values before SCT were mainly seen in patients with acute leukemias (ALL, AML and MDS), who had a pathologic T-score of −1.23 in contrast to CML patients (P = 0.001) ( Table 2 ). Twenty-one of 38 patients (55%) with acute leukemias had osteopenia or osteoporosis before SCT; only 5/15 patients (33%) with CML had osteopenia before SCT; none of them had osteoporosis (Figure 2) . A significant loss of bone mass occurred after SCT and Tscore values fell from low normal values before SCT to −1.55 after 6 and −1.71 after 12 months. Thirteen percent trabecular bone was lost after 6 months (P Ͻ 0.001) and 16.9% after 12 months. Bone mass loss affected cortical bone as well and 9.8% was lost in the first 6 months after SCT (P Ͻ 0.001). 
Figure 1
Prevalence of osteopenia (T-score Ͻ −1.0 and Ͼ −2.5) and osteoporosis (T-score Ͻ −2.5) before and after SCT.
Figure 2
Prevalence of pathologic bone mineral density (T-score Ͻ −1.0) in patients with acute leukemias and CML.
However, after 12 months cortical bone had partially recovered (Table 2) .
After 6 months 24/36 patients (67%) had pathologic Tscores below −1.0 and 20/32 patients (62%) after 12 months (Figure 1) .
Loss of bone mass after SCT was observed in all patients, but was most pronounced in patients with CML. T-score values dropped from 0.62 before SCT to −2.47 after 1 year in these patients (P = 0.018) ( Table 2 ). In patients with acute leukemias median T-score declined from −1.23 to −1.40 after 12 months, but the main loss occurred within the first 6 months (P = 0.48). Between 6 and 12 months a significant gain of bone mass was observed in patients with acute leukemias without reaching pre-SCT levels ( Table 2) . Bone mineral density in both patient groups did not differ significantly after SCT (Figure 2 ). Five patients with newly developed osteoporosis after SCT lost 2 to 5 cm body height, 2/5 suffered painful vertebral fractures without neurologic deficit.
Leukemia
Twenty-five patients underwent further BMD analysis 18 to 24 months after SCT. Only 2/25 had a further decrease in BMD and had developed osteoporosis, one with and one without chronic GVHD. Sixteen of 25 had unchanged values. Seven of 25 had an increase in BMD; after diagnosis of osteoporosis 6 months after SCT all seven had received continuous oral calcium and vitamin D substitution and 2/7 had received additionally biphosphonates. Median T-score was −1.97 at 24 months without significant difference to 12 months values.
Donor status, age, sex and amenorrhea had no significant impact on BMD before and after SCT.
Nine of 19 analyzed patients with acute GVHD (47%) developed osteoporosis after 6 months, compared to 2/20 (10%) without acute GVHD. BMD in patients with acute GVHD was significantly lower with a median T-score of −2.39 compared to −0.99 (P = 0.006) in those without GVHD. There was a trend to lower BMD in those with more severe grades of acute GVHD, but the differences were not significant. After 12 months, BMD for patients with and without GVHD were equal.
Biochemical markers of bone metabolism
Before SCT, median DPD (normal values: males 2.5-5.5, females 2.5-6.5 mmol/l) and PYD (normal values: males 12.8-25.6, females 16.0-37.0 nmol/mmol) excretion was increased to almost twice the upper normal limit. Crosslinks excretion was increased in 15/33 patients (45%), 12/20 patients (60%) with acute leukemias, but only 3/13 (23%) with CML (P = 0.014). Immediately after SCT, DPD and PYD excretion values fell to lower normal values for 4 to 5 weeks in all patients irrespective of the underlying diagnosis. Thereafter values increased to pathologic levels again and remained elevated. High normal values were observed after 1 year (Figure 3) .
Six weeks after SCT crosslinks excretion was higher in patients with acute GVHD compared to those without GVHD (for DPD: P = 0.0011; PYD = 0.0043) and after 6 months urinary values were higher in patients still on intensive immunosuppression (P = 0.042). Chronic GVHD, sex, donor status and age had no significant influence on crosslinks excretion.
Vitamin D homeostasis
Before SCT 22/57 patients (39%) had pathologic vitamin D plasma concentrations, but the median was within the lower normal range (75-175 pmol/l). Immediately after SCT, hypovitaminosis developed in all patients. Constantly reduced vit- PTH and BAP values increased slightly 6 weeks after SCT, but the rise was not significant. Calcium and phosphate concentration remained grossly unchanged after SCT.
Discussion
There is a growing interest in changes of bone metabolism after SCT, since osteoporosis could severely impair quality of life of long-term surviving patients. Recent studies have suggested an increased risk for osteoporosis after SCT.
14, 15 We observed a high frequency of osteopenia and osteoporosis in 49% of patients before SCT signalling the influence of SCTindependent factors on bone metabolism. Children with hematologic and oncologic malignancies have reduced BMD after conventional chemotherapy 16, 17 and long-term survivors of childhood cancer have a significantly reduced bone mass at a mean age of 25. 18 Because peak bone mass is attained at age 25 to 30, and peak bone mass is a major determinant of BMD at older age, it can be assumed that these patients have an increased risk for osteoporosis in later life.
Our findings show that osteopenia and osteoporosis develop after polychemotherapy in adults as well. BMD and urinary excretion of collagen type I metabolites before SCT showed a highly significant dependence on the underlying disease and patients with acute leukemias were mainly affected (Figure 2) . Most of these patients had experienced intensive polychemotherapy and were only shortly off therapy at the time of SCT. Intensive chemotherapy seems to have a major toxic effect on bone metabolism and immobilization and steroid-containing therapy will probably influence bone mass as well. Because one third of the CML patients had osteopenia before SCT, the less toxic therapy in these mostly outpatients could also have a damaging effect on bone, although so far no consistent effect of IFN-␣ on osteoblasts or osteoclasts has been shown. 19 We suppose that chemotherapy or the underlying disease damaged or reduced osteoblasts and osteoclasts, thereby leading to a serious disturbance of the balanced coupling of bone resorption and bone forming even before SCT.
After SCT, the loss in bone mass affected all patients, but those with higher pretreatment values had a steeper decline and lower values after 1 year (table 2) . We can only speculate that the older age of CML patients (median age 40 years in our study population) compared to patients with acute leukemias (median age 31 years) made them more susceptible to changes in bone mineral density due to the toxic effect of conditioning therapy and immobilization.
BMD was lost early after SCT; in some patients a rapid loss of BMD could already be observed 3 months after SCT by QCT (data not shown). High-dose conditioning therapy and immobilization during bone marrow aplasia are most likely to be responsible for early loss of bone mass. This is in line with our findings, that 12 months after SCT, BMD was either not significantly lower than after 6 months or even began to rise again (Table 2 ). In those patients followed for more than 1 year after SCT, a further decline of BMD was rare. Taking into consideration the small number of patients 18 to 24 months after SCT, these data indicate that early control of BMD is most important in detecting patients at risk.
Intensive immunosuppression with steroids and CsA added to the catabolic effect on bone density, which is illustrated in the lower BMD and increased crosslinks excretion in patients with acute GVHD.
The devastating effect of immunosuppressive therapy on bone metabolism has also been demonstrated in patients after transplantation of kidney, 20 heart, 21 lung 22 and liver. 23 Using QCT instead of dual X-ray absorptiometry (DXA) enabled us to perform a separate analysis of trabecular and cortical bone. Interestingly, bone loss after SCT affected not only trabecular bone, but also the seemingly more inactive cortical bone. Analysis of enzyme activities of the major oxidative pathways in trabecular and cortical bone have shown, that cortical bone has a high oxidative activity as well. 24 Nevertheless, trabecular bone loss was more pronounced than cortical bone loss with partial recovery of cortical bone after 12 months.
The rapid fall of crosslinks excretion after SCT was very surprising to us and is in contrast to the results of other groups. 14, 15 Low renal excretion correlated with bone marrow aplasia and immobilization. Thereafter, levels increased to pathologic values and remained elevated for 1 year after SCT. We hypothesize, that destruction of osteoprogenitor cells occurs together with other myeloid progenitor cells due to myeloablative therapy. Owing to the lack of osteoclasts, bone resorption is diminished in the short run. After hematopoietic reconstitution, osteoclast formation slowly normalizes and bone resorption is obviously stimulated once again. Toxic effects on mesenchymal cells will probably also damage osteoblast regeneration. Immunosuppressive therapy, malnutrition and delayed mobilization after discharge from the hospital could add to the chronification of bone loss.
Very striking was the profound and prolonged vitamin D deficiency in our patients. Immobilization of hospitalized patients is known to lead to rapid changes in calcium metabolism with decreased vitamin D levels. 25 Due to isolation, multiple infusions, general weakness and infections, physical activity is reduced during high-dose chemotherapy and bone marrow aplasia in these patients. Furthermore, vitamin D is known to play a role in the differentiation process of hematopoietic precursor cells. 26 Therefore, the demand for vitamin D might be increased after allogeneic SCT. Most likely, the vitamin D and calcium supplementation in our patients was insufficient in order to meet the increased demand. A decline in vitamin D concentrations after SCT was also reported by others, but they checked vitamin D values only shortly after SCT. 15 We demonstrate a long-lasting vitamin D deficiency beyond the acute phase after SCT, when patients have left the hospital. Nutritional restrictions, the generally recommended UV protection and gastrointestinal disturbances may lead to this prolonged vitamin D deficiency.
In conclusion, osteopenia and osteoporosis are frequently encountered in adults with hematologic diseases after conventional therapy. Patients with intensive pre-treatment are mainly affected. A rapid bone loss is observed early after SCT. Patients with higher pre-SCT BMD show the greatest loss of bone mass after SCT. Radiologic and biochemical markers of BMD indicate a prolonged disturbance of bone metabolism. Routine calcium and vitamin D supplementation only during hospitalization seems to be insufficient to prevent bone loss. Several factors add to the toxic effect on the bone.
We propose that measurement of BMD should be performed at least before and 6 months after SCT to detect a relevant loss of BMD. Prophylactic and therapeutic strategies for these patients have to be improved and determined in clinical studies.
